Stock Market & Financial Investment News

News Breaks November 16, 2012 07:24 EDT NUVA Correction: NuVasive upgraded to Overweight from Equal Weight at First Analysis First Analysis upgraded NuVasive based on valuation and its attractive product portfolio. Price target is $17. News For NUVA From The Last 14 Days Check below for free stories on NUVA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 12, 2013 10:20 EDT NUVA NuVasive new royalty rates a modest negative, says Wells Fargo Subscribe for More Information 05:25 EDT NUVA NuVasive announces court ruling, intends to appeal verdict in Medtronic case NuVasive announced that it received a ruling from the U.S. District Court in regards to ongoing royalty rates for Phase I of its patent litigation with Medtronic. As part of the verdict in Phase I of the litigation, royalty rates were determined by the jury as follows: 10% on certain of NuVasive's CoRoent XL implants and 3% on certain MaXcess retractors and related products. Before the appeal in Phase I could move forward, the Court was required to determine the ongoing royalty rates applicable to these products during the period of time following the verdict. Medtronic requested ongoing royalty rates of 36% on the applicable NuVasive CoRoent XL implants and 11% on the applicable MaXcess retractors and related products. However, in the ruling received, the Court ordered royalty rates of 13.75% on the applicable CoRoent XL implants and 8.25% on the applicable MaXcess retractors. Since September 2011, NuVasive has been accruing an estimated litigation royalty expense based on the royalty rates used in the jury's original calculation of lost profits and monetary damages. Prior to the post-verdict rates issued by the Court, the company had expected litigation royalty expense of approximately $11M for FY13. The new royalty rates determined today will increase that expected litigation royalty expense for 2013 by approximately $5M. In addition, in the current quarter, the company will record an approximate $6.5M charge to account for the historical difference between the post-verdict royalty rates determined today and the rates that were being used to calculate the litigation royalty expense accruals since September 2011. The vast majority of the litigation royalty expense accruals will end in February 2015 as certain Medtronic patents expire. As the verdict is being appealed, the company will accrue to the higher rates determined and will begin to escrow funds on a go-forward basis. Sign up for a free trial to see the rest of the stories you've been missing.